Dr Lal PathLabs Limited has announced robust Q2 FY26 financial results along with major corporate actions, including a 1:1 bonus issue and a ₹7 per share second interim dividend. The diagnostics major also approved an increase in authorised share capital and introduced a new employee stock option plan, marking another quarter of strong performance and shareholder rewards.
For the quarter ended September 30, 2025, the company reported consolidated revenue from operations of ₹7,306 million, up 9.1% quarter-on-quarter and 10.7% year-on-year. Profit after tax rose to ₹1,522 million from ₹1,308 million in Q2FY25, reflecting a 16.4% annual growth.
Total income stood at ₹7,554 million, while total expenses were ₹5,518 million, leading to a profit before tax of ₹2,036 million. The company’s EBITDA margin improved slightly due to higher revenues and efficient cost management.
The board approved a 1:1 bonus issue, 1 new equity share for every existing share held. Approximately 8,37,75,100 new shares will be issued, increasing paid-up capital from ₹83.8 crore to ₹167.5 crore.
The bonus shares will be issued from the Securities Premium Account, with sufficient reserves of ₹1,247.85 million. Additionally, a second interim dividend of ₹7 per equity share (70% on ₹10 face value) has been declared, with a record date of November 7, 2025.
Read More:Nippon Life India Asset Management Reports Q2 FY26 Results; AUM at ₹7.61 Trillion!
The board approved an increase in authorised share capital from ₹107.96 crore to ₹200 crore, subject to shareholder approval. It also introduced the “Dr Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025),” which will draw from the existing ESOP 2022 pool. These actions reflect the company’s focus on expanding its capital base and incentivising employees for long-term growth.
As of September 30, 2025, Dr Lal PathLabs reported total assets of ₹29,512 million and total equity of ₹24,221 million. The company maintained a strong liquidity position with ₹1,161 million in cash and equivalents and ₹5,461 million in investments. Goodwill stood at ₹5,281 million, and property, plant, and equipment were valued at ₹2,951 million. The paid-up equity capital before the bonus issue was ₹838 million.
Including this latest announcement, shareholders will receive total dividends of ₹13 per share for H1FY26-₹6 each from the first and final dividends, and ₹7 from the second interim dividend. The consistent dividend payouts underscore the company’s strong cash generation and commitment to shareholder value creation.
On October 31, 2025, Dr Lal PathLabs share price opened at ₹3,089.90 on NSE, above the previous close of ₹3,089.40. During the day, it surged to ₹3,178.00 and dipped to ₹3,063.00. The stock is trading at ₹3,139.00 as of 2:22 PM. The stock registered a moderate gain of 1.61%.
Over the past week, it has declined by 0.16%, over the past month, it has declined by 0.94%, and over the past 3 months, it has declined by 0.19%.
Dr Lal PathLabs continues its upward growth trajectory, supported by solid revenue expansion, margin stability, and strategic capital management. With a 1:1 bonus issue, ₹7 interim dividend, and double-digit profit growth, the company reinforces its position as a leading diagnostics brand in India, delivering sustained shareholder value.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Oct 31, 2025, 3:15 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN